While GLP-1 agonists may shine for weight management, SGLT2 inhibitors dominate when kidney or heart protection is the priority
The hyperacute phase is characterized by rapid antioxidant failure, creating a narrow window for direct inhibitors (Liu Z., 2025)
Supplements, including probiotics and plant-derived products, are safe to use in clinical practice but, high-quality evidence of efficacy is currently lacking
Currently, GLP-1 has been a therapeutic target for its function as an anti-inflammatory mediator as a potential avenue for neuroprotection
The medications differ in potency and in how they are dosed, and that affects how aggressively appetite drops, which in turn affects nutrient risk
This causes sudden, intense pain and swelling, common during gout attacks